Oct 25 (Reuters) - AbbVie Inc on Friday reported stronger-than-expected results for the third quarter, as booming sales of its Humira arthritis treatment and Synthroid thyroid replacement drug more ...

AbbVie (ABBV) posted better-than-expected financials for Q4 2025 as the company’s former best seller, Humira, exceeded Street forecasts, offsetting a mixed performance from its newer immunology drugs, ...

Feb 4 (Reuters) - ‌AbbVie forecast 2026 profit above Wall ‌Street estimates on Wednesday after the drugmaker posted a fourth-quarter results beat driven primarily by better-than-expected sales of its ...

AbbVie’s solid stock performance is driven by rising investor optimism as the company has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, which once generated ...

Sees FY24 U.S Humira sales $7.4B, down $400M from prior view. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks ...

Robert Michael, CEO & Chairman of the Board, reported "record net sales and exceeded our financial commitments, advanced our pipeline across all stages of development and acquired new sources of ...

AbbVie ABBV stock slipped below its 50-day simple moving average (SMA) on March 13, after consistently trading above it since ...